C&R Research Inc. (KOSDAQ:359090)
550.00
+39.00 (7.63%)
At close: Jun 4, 2026
C&R Research Revenue
C&R Research had revenue of 14.76B KRW in the quarter ending March 31, 2026, a decrease of -13.39%. This brings the company's revenue in the last twelve months to 62.70B, up 1.12% year-over-year. In the year 2025, C&R Research had annual revenue of 64.98B with 8.87% growth.
Revenue (ttm)
62.70B
Revenue Growth
+1.12%
P/S Ratio
0.50
Revenue / Employee
122.94M
Employees
510
Market Cap
31.61B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 64.98B | 5.29B | 8.87% |
| Dec 31, 2024 | 59.69B | 4.59B | 8.32% |
| Dec 31, 2023 | 55.10B | 6.63B | 13.68% |
| Dec 31, 2022 | 48.47B | 5.30B | 12.28% |
| Dec 31, 2021 | 43.17B | 15.97B | 58.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| HLB bioStep | 73.96B |
| DreamCIS | 69.87B |
| DT&CRO CO. | 47.77B |
| WOOJUNG BIO | 40.30B |
| BioInfra | 23.21B |
| P&K Skin Research Center | 22.56B |
| Penetrium Bioscience | 9.74B |
| Curachem | 6.02B |